Ekso Bionics reported a strong third quarter with a 38% increase in revenue, reaching $4.6 million, driven by solid sales of EksoHealth devices and a record number of EVO unit sales. The company's gross profit also increased by 46% to $2.5 million, with a gross margin of approximately 53%.
Reported revenue of $4.6 million in Q3 2023, a 38% increase year-over-year.
Sold a total of 41 EksoHealth devices in Q3 2023.
Achieved a record quarter of EVO unit sales.
Gross profit of $2.5 million in Q3 2023, compared to $1.7 million in the same period last year.
Ekso Bionics anticipates potential market expansion for home and community devices for spinal cord injury patients, pending CMS rule changes and application approval.